To aloud OPDIVO in the UK not just Scotland sooner then a year.

Advanced Squamous NSCLC Trial
In a clinical trial of 272 patients whose advanced squamous NSCLC had spread or grown after treatment with platinum-based chemotherapy, 135 were treated with OPDIVO, 137 were treated with chemotherapy (docetaxel). OPDIVO was shown to reduce the risk of dying by 41% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO were still alive at 9.2 months, compared to 6 months with chemotherapy (docetaxel). OPDIVO will not work for everyone. Individual results may vary

Sign Petition
Sign Petition
You have JavaScript disabled. Without it, our site might not function properly.

Privacy Policy

By signing, you accept Care2's Terms of Service.
You can unsub at any time here.

Having problems signing this? Let us know.